Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023 16:30 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
October 17, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Strategic Collaboration with Roche to Discover Novel Molecular Glue Degraders Targeting Cancer and Neurological Diseases
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
October 17, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Interim PK/PD and Clinical Data for MRT-2359 in Phase 1/2 Trial for MYC-Driven Solid Tumors
Monte Rosa Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 07:15 ET
|
Monte Rosa Therapeutics, Inc.
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug...
Monte Rosa Therapeutics Appoints Dr. Anthony M. Manning to Board of Directors
July 26, 2023 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics to Present at Upcoming Investor and Industry Conferences
May 30, 2023 16:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...
Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
May 23, 2023 07:30 ET
|
Monte Rosa Therapeutics, Inc.
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression in autoimmunity models, supporting potential applications across multiple...
Monte Rosa Therapeutics Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:30 ET
|
Monte Rosa Therapeutics, Inc.
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 in MYC-driven solid tumors in the second half of 2023Cash runway into 2025 supports operations and advancement of pipeline of...
Monte Rosa Therapeutics Presents Preclinical Data from GSPT1 Degrader Program Focused on MYC-Driven Cancers at AACR 2023
April 17, 2023 16:30 ET
|
Monte Rosa Therapeutics, Inc.
Preclinical data demonstrate preferential activity of MRT-2359, an orally bioavailable GSPT1-directed molecular glue degrader, in MYC-driven tumor cellsPhase 1/2 clinical trial of MRT-2359 ongoing in...
Monte Rosa Therapeutics Appoints Dr. Jan Skvarka to Board of Directors
March 23, 2023 07:30 ET
|
Monte Rosa Therapeutics, Inc.
BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today...